As of 1/1/2015, the current TRIAL PROPOSAL has received funding by the European Union Framework Program on Research and Innovation as a part of a project titled "Repair of tissue and organ damage in refractory chronic graft versus host disease after hematopoietic stem cell transplantation by the infusion of purified allogeneic donor regulatoryT lymphocytes" (acronym TREGeneration, code 643776). The project includes a set of proposals by different European institutions (University of Lisbona, University of Liege, University of Regensburg and the University of Bologna) all investigating the role of Treg DLI in the treatment of chronic GVHD. The GRANT AGREEMENT signed with the EUROPEAN COMMISSION is attached to the proposal.